About Us
Company profile
Jingjing Pharmaceutical Co., Ltd. was established in October 2007, covering an area of 310 mu, with a registered capital of 257.28 million yuan and more than 700 employees. It is a national high-tech enterprise and a national technological innovation demonstration enterprise specializing in the research, development, production and sales of sterile APIs, Amino acids and Vitamin nutrition fortifiers.
In December 2015, it was successfully listed on the New Third Board securities market with the security code of 835033. Since its listing, it has received attention and recognition from all aspects in the capital market, introduced a number of market makers and strategic investment institutions, and entered the innovation layer in the first batch. After listing, the company has implemented three targeted additional offerings, with a total financing of 240 million yuan, mainly invested in core technology research and development, extension of the main product industry chain, project technology innovation, and replenishment of working capital, forming a number of core technical barriers, and gradually establishing the company's leading position in the subdivided industries.
After years of tackling key problems, the company's technical team has obtained 67 patents, including 39 invention patents. It has successively passed a series of certifications such as high-tech enterprises, national and local joint engineering laboratories, provincial enterprise technology centers, and provincial engineering laboratories. It has set up academician workstations, and has been rated as "Hebei Technological Innovation Demonstration Enterprise", "Hebei Small and Medium sized Technological Enterprises", and the first batch of "specialized, refined, and new" demonstration enterprises in Hebei Province, It has successively won the honors of "China's Top 100 Innovation Demonstration Enterprises", "China's Reform and Innovation Demonstration Unit", and was included in the New Third Board "Innovation Index" and "Third Board Medicine" index model stocks.
Core technologies and products
Over the years, through continuous technological innovation, the company has formed two major categories of products: 1)Sterile API products with crystallization technology as the core advantage. Through the "Academician Workstation" technology platform, our company has continuously made technological breakthroughs in sterile API crystallization technology, and has formed a competitive advantage in the pharmaceutical industry at home and abroad, At present, our company's sterile API products (Arginine, Sodium carbonate anhydrous, and L-Alanyl-L-Glutamine) can meet the different special needs of different sterile powder injection customers, achieved one-to-one customized services for customers, reached the domestic leading level, and had a high market share; 2)Amino acids and Vitamin series products with biological enzyme catalysis technology as the core advantage. Biological enzyme catalysis technology has been listed in the seven emerging industrial technologies that are supported and developed by the 13th Five Years Plan of China government. Our company focuses on the use of the research and development platform jointly established with international well-known biological enzyme research and development institutions, we are the first in China to realize the industrialization of the production of Amino acid series derivatives and Vitamins using biological enzyme catalysis technology, with broad market prospects, It has strongly competitive advantages.
Development planning
In the future,the company will rely on the advantages of sterile API crystallization technology and biological enzyme catalysis technology, pool the wisdom of the team, gather resources from all sides, and focus on the future strategic objectives. Firstly, the company will rely on core technology to achieve the extension of the original small variety of Amino acids to large variety strategy, accelerate the industrialization process of new products, and continue to improve the company's leading edge in the biomedical health segment industry; Secondly, accelerate the listing process of Beijing Stock Exchange, and help enterprises achieve leapfrog high-quality development by virtue of capital market advantages.
